Bisphosphonates are associated with reduced risk of colorectal cancer: A systematic review and meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 3, 2013, Pages

  Singh, Siddharth ^a   Singh, Abha Goyal ^a   Murad, Mohammad Hassan ^a   Limburg, Paul J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bone Mass; Cancer Risk; Osteoporosis Drug; Postmenopausal

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; DATA BASE; META ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84874560000     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.026     Document Type: Article

References (40)

1. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005, 353:595-603.
2. Gnant M., Clézardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 2012, 38:407-415.
3. Green J., Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol 2010, 37(Suppl 1):S3-S11.
4. Pazianas M., Russell R.G. Potential therapeutic effects of oral bisphosphonates on the intestine. Ann N Y Acad Sci 2011, 1240:E19-E25.
5. Sewing L., Steinberg F., Schmidt H., et al. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008, 13:782-789.
6. Chlebowski R.T., Chen Z., Cauley J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590.
7. Liu Y., Zhao S., Chen W., et al. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature. Clin Breast Cancer 2012, 12:276-281.
8. Monsees G.M., Malone K.E., Tang M.T., et al. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2011, 103:1752-1760.
9. Mauri D., Valachis A., Polyzos N.P., et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease?. A meta-analysis of randomized controlled trials. J Natl Compr Cancer Netw 2010, 8:279-286.
10. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
11. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
12. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
13. Zauber A.G., Winawer S.J., O'Brien M.J., et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012, 366:687-696.
14. Rennert G., Pinchev M., Rennert H.S., et al. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011, 29:1146-1150.
15. Singh H., Nugent Z., Demers A., et al. Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study. Cancer 2012, 118:1236-1243.
16. Khalili H., Huang E.S., Ogino S., et al. A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol 2012, 30:3229-3233.
17. Higgins J.P.T. Cochrane handbook for systematic reviews of interventions. The Cochrane collaboration 2011, John Wiley & Sons, Ltd., Chichester, UK. J.P.T. Higgins (Ed.).
18. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
19. Wells G.A., Shea B., O'Connell D., Peterson J., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2012, Accessed September 5, 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
21. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
22. Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
23. Pazianas M., Abrahamsen B., Eiken P.A., et al. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register based cohort study. Osteoporos Int 2012, 23:2693-2701.
24. Chiang C.H., Huang C.C., Chan W.L., et al. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study. J Bone Miner Res 2012, 27:1951-1958.
25. Cardwell C.R., Abnet C.C., Veal P., et al. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 2012, 131:E717-E725.
26. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011, 89:434-441.
27. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), Bethesda, MD: National Cancer Institute. Available at: Accessed September 15, 2012. http://seer.cancer.gov/csr/1975_2009_pops09/.
28. Bardou M., Barkun A., Martel M. Effect of statin therapy on colorectal cancer. Gut 2010, 59:1572-1585.
29. Boghossian S., Hawash A. Chemoprevention in colorectal cancer-where we stand and what we have learned from twenty year's experience. Surgeon 2012, 10:43-52.
30. Din F.V., Theodoratou E., Farrington S.M., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59:1670-1679.
31. Lin K.J., Cheung W.Y., Lai J.Y., et al. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012, 130:419-430.
32. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012, 18:3524-3531.
33. Sato K., Kimura S., Segawa H., et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005, 116:94-99.
34. Todaro M., D'Asaro M., Caccamo N., et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009, 182:7287-7296.
35. Jedinak A., Dudhgaonkar S., Sliva D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 2010, 215:242-249.
36. Ballester I., Daddaoua A., López-Posadas R., et al. The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Br J Pharmacol 2007, 151:206-215.
37. Sassa S., Okabe H., Nemoto N., et al. Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 2009, 29:4615-4619.
38. Cho E., Smith-Warner S.A., Spiegelman D., et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004, 96:1015-1022.
39. Watts N.B., Lewiecki E.M., Miller P.D., et al. National Osteoporosis Foundation 2008 clinician's guide to prevention and treatment of osteoporosis and the World Health Organization fracture risk assessment tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008, 11:473-477.
40. Tosteson A.N., Melton L.J., Dawson-Hughes B., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447.